Literature DB >> 30613962

Immunogenomic analysis reveals LGALS1 contributes to the immune heterogeneity and immunosuppression in glioma.

Qun Chen1, Bo Han1, Xiangqi Meng1, Chunbin Duan1, Changxiao Yang1, Zhenyu Wu1, Dinislam Magafurov1,2, Shihong Zhao1, Shamil Safin2, Chuanlu Jiang1, Jinquan Cai1.   

Abstract

Mutualistic and dynamic communication between tumour cells and the surrounding microenvironment accelerates the initiation, progression, chemoresistance and immune evasion of glioblastoma (GBM). However, the immunosuppressive mechanisms of GBM has not been thoroughly elucidated to date. We enrolled six microenvironmental signatures to identify glioma microenvironmental genes. The functional enrichment analysis such as ssGSEA, ESTIMATE algorithm, Gene Ontology, Pathway analysis is conducted to discover the potential function of microenvironmental genes. In vivo and in vitro experiments are used to verify the immunologic function of LGALS1 in GBM. We screen eight glioma microenvironmental genes from glioma databases, and discover a key immunosuppressive gene (LGALS1 encoding Galectin-1) exhibiting obviously prognostic significance among glioma microenvironmental genes. Gliomas with different LGALS1 expression have specific genomic variation spectrums. Immunosuppression is a predominate characteristic in GBMs with high expression of LGALS1. Knockdown of LGALS1 remodels the GBM immunosuppressive microenvironment by down regulating M2 macrophages and myeloid-derived suppressor cells (MDSCs), and inhibiting immunosuppressive cytokines. Our results thus implied an important role of microenvironmental regulation in glioma malignancy and provided evidences of LGALS1 contributing to immunosuppressive environment in glioma and that targeting LGALS1 could remodel immunosuppressive microenvironment of glioma.
© 2019 UICC.

Entities:  

Keywords:  zzm321990LGALS1; glioblastoma; immunosuppression; microenvironment; prognosis

Mesh:

Substances:

Year:  2019        PMID: 30613962     DOI: 10.1002/ijc.32102

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  32 in total

Review 1.  Multiple strategies to improve the therapeutic efficacy of oncolytic herpes simplex virus in the treatment of glioblastoma.

Authors:  Zhengjun Zhou; Junjie Tian; Wenyan Zhang; Wei Xiang; Yang Ming; Ligang Chen; Jie Zhou
Journal:  Oncol Lett       Date:  2021-05-03       Impact factor: 2.967

2.  LINC01564 Promotes the TMZ Resistance of Glioma Cells by Upregulating NFE2L2 Expression to Inhibit Ferroptosis.

Authors:  Chixing Luo; Chuansheng Nie; Yibin Zeng; Kang Qian; Xudong Li; Xuan Wang
Journal:  Mol Neurobiol       Date:  2022-04-14       Impact factor: 5.590

3.  Risk characteristics with seven epithelial-mesenchymal transition-related genes are used to predict the prognosis of patients with hepatocellular carcinoma.

Authors:  Xianqing Shi; Shuhuan Tu; Liqun Zhu
Journal:  J Gastrointest Oncol       Date:  2021-08

Review 4.  Pharmacological targeting of the tumor-immune symbiosis in glioblastoma.

Authors:  Lizhi Pang; Fatima Khan; Madeline Dunterman; Peiwen Chen
Journal:  Trends Pharmacol Sci       Date:  2022-05-07       Impact factor: 17.638

5.  Prognostic Value and Biological Function of Galectins in Malignant Glioma.

Authors:  Hongtao Zhu; Dan Liu; Lidong Cheng; Jingdian Liu; Guanghui Wang; Huan Li; Yang Zhang; Hailong Mi; Suojun Zhang; Kai Shu; Xingjiang Yu
Journal:  Front Oncol       Date:  2022-06-24       Impact factor: 5.738

6.  EMP3 mediates glioblastoma-associated macrophage infiltration to drive T cell exclusion.

Authors:  Qun Chen; Jing Jin; Xin Huang; Fan Wu; Hongguang Huang; Renya Zhan
Journal:  J Exp Clin Cancer Res       Date:  2021-05-08

Review 7.  Glial and myeloid heterogeneity in the brain tumour microenvironment.

Authors:  Brian M Andersen; Camilo Faust Akl; Michael A Wheeler; E Antonio Chiocca; David A Reardon; Francisco J Quintana
Journal:  Nat Rev Cancer       Date:  2021-09-28       Impact factor: 69.800

8.  A novel prognostic models for identifying the risk of hepatocellular carcinoma based on epithelial-mesenchymal transition-associated genes.

Authors:  Chen Xiong; Guifu Wang; Dousheng Bai
Journal:  Bioengineered       Date:  2020-12       Impact factor: 3.269

9.  Investigation of Genetic Determinants of Glioma Immune Phenotype by Integrative Immunogenomic Scale Analysis.

Authors:  Binghao Zhao; Yuekun Wang; Yaning Wang; Congxin Dai; Yu Wang; Wenbin Ma
Journal:  Front Immunol       Date:  2021-06-16       Impact factor: 7.561

Review 10.  Roles of Long Noncoding RNAs in Conferring Glioma Progression and Treatment.

Authors:  Jie Qin; Chuanlu Jiang; Jinquan Cai; Xiangqi Meng
Journal:  Front Oncol       Date:  2021-06-11       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.